                         SEQUENCE LISTING

<110>  MERCK PATENT GMBH
 
<120>  Metabolic biomarkers for predicting responsiveness to FGF-18 compound

<130>  P 17/235

<150>  EP17194220.4
<151>  29.09.2017

<150>  EP18169324.3
<151>  25.04.2018

<160>  4    

<170>  PatentIn version 3.5

<210>  1
<211>  207
<212>  PRT
<213>  Homo sapiens

<220>
<223>  human FGF-18

<400>  1

Met Tyr Ser Ala Pro Ser Ala Cys Thr Cys Leu Cys Leu His Phe Leu 
1               5                   10                  15      

Leu Leu Cys Phe Gln Val Gln Val Leu Val Ala Glu Glu Asn Val Asp 
            20                  25                  30          

Phe Arg Ile His Val Glu Asn Gln Thr Arg Ala Arg Asp Asp Val Ser 
        35                  40                  45              

Arg Lys Gln Leu Arg Leu Tyr Gln Leu Tyr Ser Arg Thr Ser Gly Lys 
    50                  55                  60                  

His Ile Gln Val Leu Gly Arg Arg Ile Ser Ala Arg Gly Glu Asp Gly 
65                  70                  75                  80  

Asp Lys Tyr Ala Gln Leu Leu Val Glu Thr Asp Thr Phe Gly Ser Gln 
                85                  90                  95      

Val Arg Ile Lys Gly Lys Glu Thr Glu Phe Tyr Leu Cys Met Asn Arg 
            100                 105                 110         

Lys Gly Lys Leu Val Gly Lys Pro Asp Gly Thr Ser Lys Glu Cys Val 
        115                 120                 125             

Phe Ile Glu Lys Val Leu Glu Asn Asn Tyr Thr Ala Leu Met Ser Ala 
    130                 135                 140                 

Lys Tyr Ser Gly Trp Tyr Val Gly Phe Thr Lys Lys Gly Arg Pro Arg 
145                 150                 155                 160 

Lys Gly Pro Lys Thr Arg Glu Asn Gln Gln Asp Val His Phe Met Lys 
                165                 170                 175     

Arg Tyr Pro Lys Gly Gln Pro Glu Leu Gln Lys Pro Phe Lys Tyr Thr 
            180                 185                 190         

Thr Val Thr Lys Arg Ser Arg Arg Ile Arg Pro Thr His Pro Ala 
        195                 200                 205         


<210>  2
<211>  170
<212>  PRT
<213>  recombinant

<220>
<223>  Truncated FGF-18 (sprifermin)

<400>  2

Met Glu Glu Asn Val Asp Phe Arg Ile His Val Glu Asn Gln Thr Arg 
1               5                   10                  15      

Ala Arg Asp Asp Val Ser Arg Lys Gln Leu Arg Leu Tyr Gln Leu Tyr 
            20                  25                  30          

Ser Arg Thr Ser Gly Lys His Ile Gln Val Leu Gly Arg Arg Ile Ser 
        35                  40                  45              

Ala Arg Gly Glu Asp Gly Asp Lys Tyr Ala Gln Leu Leu Val Glu Thr 
    50                  55                  60                  

Asp Thr Phe Gly Ser Gln Val Arg Ile Lys Gly Lys Glu Thr Glu Phe 
65                  70                  75                  80  

Tyr Leu Cys Met Asn Arg Lys Gly Lys Leu Val Gly Lys Pro Asp Gly 
                85                  90                  95      

Thr Ser Lys Glu Cys Val Phe Ile Glu Lys Val Leu Glu Asn Asn Tyr 
            100                 105                 110         

Thr Ala Leu Met Ser Ala Lys Tyr Ser Gly Trp Tyr Val Gly Phe Thr 
        115                 120                 125             

Lys Lys Gly Arg Pro Arg Lys Gly Pro Lys Thr Arg Glu Asn Gln Gln 
    130                 135                 140                 

Asp Val His Phe Met Lys Arg Tyr Pro Lys Gly Gln Pro Glu Leu Gln 
145                 150                 155                 160 

Lys Pro Phe Lys Tyr Thr Thr Val Thr Lys 
                165                 170 


<210>  3
<211>  6
<212>  PRT
<213>  recombinant

<220>
<223>  Marker CTX-II

<400>  3

Glu Lys Gly Pro Asp Pro
1               5      


<210>  4
<211>  10
<212>  PRT
<213>  recombinant

<220>
<223>  Marker ProC2

<400>  4

Gln Asp Val Arg Gln Pro Gly Pro Lys Gly
1               5                   10    
